Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: the label excerpt supports that a specific antacid product (Maalox TC) reduces atorvastatin exposure (AUC and Cmax), but most other claims (mechanisms, aluminum/magnesium vs calcium carbonate comparisons, and spacing/timing guidance including H2 blocker/PPI distinctions) are not supported by the provided label text.
Category Scores
Accurate Statements
Some antacids can reduce absorption of atorvastatin (Lipitor), which may lower how much of the drug reaches the bloodstream and therefore reduce its effect.
12.3 Pharmacokinetics (Table 3): Maalox TC shows decreased atorvastatin exposure (↓AUC and ↓Cmax). The label supports reduced exposure; it does not explicitly justify the broader wording about 'effect' beyond exposure changes in the provided excerpt.
Unsupported Statements
Antacid products containing aluminum or magnesium are most often associated with reduced absorption of some medications when taken together.
No aluminum/magnesium-specific generalization is present in the provided label sections.
Antacid products that contain calcium carbonate are associated with a lower interaction risk than aluminum/magnesium products.
No calcium carbonate vs aluminum/magnesium risk comparison is present in the provided label sections.
Spacing Lipitor out from antacids rather than taking them back-to-back can prevent absorption issues.
No administration spacing guidance for antacids is provided in the supplied label excerpts.
The recommended timing between Lipitor and antacids can vary by antacid formulation.
No antacid-specific timing recommendations or formulation-dependent timing guidance is included in the supplied label excerpts.
H2 blockers (such as famotidine) reduce stomach acid over hours.
No H2 blocker pharmacodynamic description is included in the provided label sections.
Proton pump inhibitors (such as omeprazole) reduce stomach acid over hours.
No PPI pharmacodynamic description is included in the provided label sections.
Antacids neutralize stomach acid quickly.
No general antacid mechanism/timing statement is present in the provided label sections.
H2 blockers and proton pump inhibitors are different from antacids and are generally aren’t managed the same way regarding spacing.
No spacing/management comparison between antacids and H2 blockers/PPIs is present in the provided label excerpts.
If Lipitor is taken right after an antacid once, the main risk is absorbing a lower dose that day.
The provided label shows exposure changes with a specific antacid product (Table 3), but does not provide advice tied to 'right after,' 'once,' or define 'main risk' as a day-specific lower dose.
Contradictions
Important Omissions
Specific, label-supported administration guidance for how to take atorvastatin with antacids (e.g., any exact spacing recommendations).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims introduce unlabelled administration/spacing and mechanistic statements that could lead to clinically meaningful changes in atorvastatin exposure. The only directly label-supported interaction evidence in the provided excerpt is reduced exposure with Maalox TC.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most interaction guidance is extrapolated beyond the provided label text (mechanisms, aluminum/magnesium vs calcium carbonate comparisons, and timing/spacing recommendations vs H2 blockers/PPIs).
Suggested Improvement
Limit claims to what the provided label excerpt supports: that the Table 3 interaction study with Maalox TC shows decreased atorvastatin AUC and Cmax. Avoid adding unsupported spacing/timing rules or mechanistic statements not present in the supplied label sections.